ARUP LABORATORIES
800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	9/22/1977
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Leflunomide Metabolite, Serum or Plasma

ARUP test code 2007460

Leflunomide Metabolite, Serum/Plasma

0.011 ug/mL L (Ref Interval: >=40.000)

INTERPRETIVE INFORMATION: Leflunomide Metabolite, Serum or Plasma

Therapeutic and toxic ranges are not well established. Concentrations greater than 40.000 ug/mL tend to correlate with improved patient outcome. A proposed therapeutic range is 50.000 - 100.000 ug/mL. Adverse reactions to Leflunomide, such as diarrhea, hypertension, and liver toxicity, do not correlate well with serum drug concentrations. Leflunomide has a potential risk for teratogenesis. For women being treated with Leflunomide who desire to become pregnant, enhanced drug elimination should be performed until plasma teriflunomide concentrations are lower than 0.020 ug/mL on two separate tests taken at least 14 days apart.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Leflunomide Metabolite, Serum/Plasma	22-220-110365	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical